^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Regimen: | BEACOPP (bleomycin + cyclophosphamide + doxorubicin hydrochloride + etoposide IV + Matulane (procarbazine hydrochloride) + prednisone + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ASSOCIATION OF BCL-2 EXPRESSING TUMOR CELLS WITH RESPONSE TO FRONTLINE CHEMOTHERAPY IN NODULAR SCLEROSIS HODGKIN LYMPHOMA
Published date:
05/12/2022
Excerpt:
Depending on the response to the 1st line therapy according to the BEACOPP-14 regimen, the subjects were divided into 2 groups....The optimal threshold value for the proportion of BCL-2+ tumor cells was 46%. Based on the established threshold, all subjects were divided into two categories: with high (≥46%) and low (<46%) BCL-2 expression....A high relative content of BCL-2+ tumor cells (>46%) is associated with treatment failures in patients with NSCHL.
